MAPT and Alzheimer disease: Our prior work using 3 different AD transgenic (Tg) mouse models, has shown that active immunization based on this approach produces a therapeutic polyclonal response that reduces all three key neuropathological features of AD, namely amyloid plaques, congophilic amyloid angiopathy (CAA) and tau related pathology, in association with significant cognitive benefits14, 15, 21, 22, 31.